Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Silmitasertib in Advanced Basal Cell Carcinoma
NCT03897036Phase 1Completed
- Sponsor
- Senhwa Biosciences, Inc.
- Start
- Apr 2019
- Primary completion
- Jan 2024
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of silmitasertib in basal cell carcinoma (BCC) (2 arms), sponsored by Senhwa Biosciences, Inc. Primary endpoint: Recommended Phase II Dose. Started Apr 2019; status: completed.
02
Drugs
silmitasertib
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT03897036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03897036.